Amryt Pharma’s Filsuvez®, the first EB-specific treatment designed to heal partial thickness wounds in Dystrophic and Junctional EB in patients 6 months and older, has been approved by the European Commission (EC) for use in the EU. This means that the treatment has been declared safe for use in humans within the EU.
Read More
The First World Congress on Rare Skin Diseases took place in Paris at the beginning of June 2022. The Congress was organised by the European Reference Network (ERN) for Skin and the Rare Skin Diseases Network of the Fondation René Torraine. Medical teams, scientists, patient representatives, policy makers and industry came together under one roof for three days.
Read More
We are delighted to share some positive news related to two new EB treatments which are currently being developed.
Read More
This blog post was co-authored by Mary Bailey.
Prof Liam Grover and his research team at the University of Birmingham are currently developing a spray that will be used to treat oral scarring, mouth ulcerations and internal blistering in EB.
Read More
We are delighted to share that the first ever EB specific treatment is one step closer to bedside in Europe.
Read More
